Amgen Falters In Core Immunology Business, But Help Is On The Horizon
2023 Guidance Raised Even Before Deal Closing
Sales of Amgen’s key immunology drugs Otezla and Enbrel plunged in Q1, impacted by inventory and competition, but the company will add a new blockbuster when its Horizon acquisition closes in June.
